Evaluation of Transtympanic Steroid Injection Dosage in Treatment of Sensorineural Hearing Loss: A Systematic Review.
- 1Northeast Ohio Medical University, College of Medicine, Ohio, United States.
- 2HEARS, LLC, United States.
Abstract
In sensorineural hearing loss treatment, transtympanic membrane (TTM) steroid injections help in recovery. However, steroid dosage distribution and patient recovery rates remains underexplored. Our systematic review compiles steroid regimens and their hearing recovery rates. PubMed, OVID, and Google Scholar. Search terms included TTM steroid and hearing loss. Inclusion criteria were measurements for human hearing recovery, full-text articles, and studies published on or before 1/20/2025. Exclusion criteria included reviews. Primary outcomes were hearing and patient recovery rates. For analysis, we focused on dose levels and simultaneous systemic steroids, and employed descriptive and exploratory study-level analyses Results: 29 articles were included. Of studies reporting gender, the distribution was 54.6% (635) male and 45.4% (528) female. 1,294 total patients received TTM steroids with distributions being: 26.0% (n=336) received 4 mg/mL dexamethasone, 25.2% (n=326) received 5 mg/mL dexamethasone, 2.7% (n=35) received 8 mg/mL dexamethasone, 3.5% (n=45) used 10 mg/mL dexamethasone, 3.1% (n=40) received 24 mg/mL dexamethasone, 31.8% (n=411) received 40 mg/mL methylprednisolone, 2.6% (n=34) received 62.5 mg/mL methylprednisolone, and 5.2% (n=67) received 125 mg/mL methylprednisolone. Hearing recovery ranged from 6.4-41 decibels (dB). The exploratory analysis did not identify significant differences in hearing recovery; however, methodological variance limits direct cross-study comparison and limits dose equivalence. Variability exists in regimen and outcomes reported. The findings of this study-level exploratory analysis should not be interpreted as evidence that a dose-response relationship does not exist. Therefore, this study provides a framework for researchers and clinicians to understand steroid regimens used to date.
Related
- Efficacy and safety of gastrodin acupoint injection as an adjunctive therapy for sensorineural hearing loss with vertigo: A randomized controlled trial
- Efficacy of Defibrinogenation Therapy for Sudden Sensorineural Hearing Loss: A Systematic Review and Meta‐Analysis
- Post-Treatment Response and Safety of Stem Cell-Based Urethral Injection Therapy for Female Stress Urinary Incontinence: A Systematic Review and Meta-Analysis
- 10-Minute vs. 4-Hour Post-Gadolinium 3D-FLAIR MRI for Sudden Sensorineural Hearing Loss: A Systematic Review and Meta-analysis.
- Study protocol of the SuDHO study: hyperbaric oxygen treatment added to standard care for acute idiopathic sudden sensorineural hearing loss – a multicentre randomised controlled trial
BibTeX
@article{nallapaneni2026evaluation,
title = {{Evaluation of Transtympanic Steroid Injection Dosage in Treatment of Sensorineural Hearing Loss: A Systematic Review.}},
author = {Sanjana Nallapaneni and Naveen S Raj and Margaret P Byars and Alexander M Belardo and Anita S Jeyakumar},
journal = {Journal of otology},
year = {2026},
month = oct,
doi = {10.26599/joto.2026.9540082},
url = {https://europepmc.org/article/MED/42996883},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Evaluation of Transtympanic Steroid Injection Dosage in Treatment of Sensorineural Hearing Loss: A Systematic Review.
AU - Sanjana Nallapaneni
AU - Naveen S Raj
AU - Margaret P Byars
AU - Alexander M Belardo
AU - Anita S Jeyakumar
PY - 2026
DA - 2026/10/01
JO - Journal of otology
DO - 10.26599/joto.2026.9540082
UR - https://europepmc.org/article/MED/42996883
AB - In sensorineural hearing loss treatment, transtympanic membrane (TTM) steroid injections help in recovery. However, steroid dosage distribution and patient recovery rates remains underexplored. Our systematic review compiles steroid regimens and their hearing recovery rates. PubMed, OVID, and Google Scholar. Search terms included TTM steroid and hearing loss. Inclusion criteria were measurements for human hearing recovery, full-text articles, and studies published on or before 1/20/2025. Exclusion criteria included reviews. Primary outcomes were hearing and patient recovery rates. For analysis, we focused on dose levels and simultaneous systemic steroids, and employed descriptive and exploratory study-level analyses Results: 29 articles were included. Of studies reporting gender, the distribution was 54.6% (635) male and 45.4% (528) female. 1,294 total patients received TTM steroids with distributions being: 26.0% (n=336) received 4 mg/mL dexamethasone, 25.2% (n=326) received 5 mg/mL dexamethasone, 2.7% (n=35) received 8 mg/mL dexamethasone, 3.5% (n=45) used 10 mg/mL dexamethasone, 3.1% (n=40) received 24 mg/mL dexamethasone, 31.8% (n=411) received 40 mg/mL methylprednisolone, 2.6% (n=34) received 62.5 mg/mL methylprednisolone, and 5.2% (n=67) received 125 mg/mL methylprednisolone. Hearing recovery ranged from 6.4-41 decibels (dB). The exploratory analysis did not identify significant differences in hearing recovery; however, methodological variance limits direct cross-study comparison and limits dose equivalence. Variability exists in regimen and outcomes reported. The findings of this study-level exploratory analysis should not be interpreted as evidence that a dose-response relationship does not exist. Therefore, this study provides a framework for researchers and clinicians to understand steroid regimens used to date.
SN - 1672-2930
SN - 2524-1753
ER -